[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626011":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":40,"centralContacts":45,"locations":28,"responsibleParty":51,"collaborators":28,"id":54,"slug":28,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":28,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":28,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":76,"overallStatus":77,"whyStopped":28,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":28},{"fullName":5,"class":6},"Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Zynrelef","EXPERIMENTAL","Periarticular injection of bupivacaine-meloxicam extended release",[13],"Combination Product: bupivacaine-meloxicam (extended release)",{"label":15,"type":16,"description":17,"interventionNames":18},"Control","ACTIVE_COMPARATOR","Periarticular injection of bupivacaine, ketorolac, and lidocaine",[19,20,21],"Drug: Bupivacaine","Drug: Ketorolac","Drug: Lidocaine (drug)",[23,29,34,37],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"COMBINATION_PRODUCT","bupivacaine-meloxicam (extended release)","These surgeons will be using Zynrelef (bupivacaine-meloxicam extended release) as a form of periarticular analgesia.",[9],null,{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":28},"DRUG","Bupivacaine","These surgeons will be using the control injection (bupivacaine + ketorolac + lidocaine) as a form of periarticular analgesia.",[15],{"type":30,"name":35,"description":32,"armGroupLabels":36,"otherNames":28},"Ketorolac",[15],{"type":30,"name":38,"description":32,"armGroupLabels":39,"otherNames":28},"Lidocaine (drug)",[15],[41],{"name":42,"affiliation":43,"role":44},"Andrew Waligora, MD","Allegheny Health Network","PRINCIPAL_INVESTIGATOR",[46],{"name":47,"role":48,"phone":49,"phoneExt":28,"email":50},"Obinna Ajah, MD","CONTACT","877-660-6777","obinna.ajah@ahn.org",{"type":44,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":28,"oldOrganization":28},"Andrew Waligora","Physician","100626011",false,"NCT07430085","Post-Operative Pain Relief: Zynrelef or Periarticular Injections in RATKA","Postoperative Pain Outcomes After Use of Bupivacaine-Meloxicam Extended-Release Solution in Robot Assisted Total Knee Arthroplasty: A Prospective Study","Inclusion Criteria:\n\nMales or females aged 18-89 years\n\nDiagnosed with knee osteoarthritis requiring surgical intervention\n\nIndicated for unilateral RATKA\n\nExclusion Criteria:\n\nPediatric, pregnant, or incarcerated patients\n\nBMI of more than 45 kg\u002Fm2\n\nProlonged opioid use history of \\>5 mg\u002Fday for \\>1 month\n\nHistory of contralateral TKA \\\u003C2 years prior to the index TKA\n\nType 1 Hypersensitivity to NSAIDs or local anesthetics\n\nDiagnosis of severe renal disease","ALL","18 Years","89 Years",{"count":64,"type":65},150,"ESTIMATED","INTERVENTIONAL",[68],"PHASE4","Prospective Cohort of patients who are scheduled for a Robot Assisted Total Knee Arthroplasty (RATKA). A prospective survey of patient reported outcome measures (Numeric Rating Scale) will be obtained postoperatively of 72 hours, as well as at the postoperative opioid consumption after 72 hours.",[71,72,73,74,75],"Periarticular Block","Osteoarthritis (OA)","Osteoarthritis (OA) of the Knee","Pain After Surgery","Knee Arthroplasty, Total",[9],"NOT_YET_RECRUITING","2026-02-24",{"date":80,"type":81},"2026-02-27","ACTUAL",{"date":83,"type":65},"2026-01-31",{"date":85,"type":65},"2028-02-28",{"name":5,"class":6}]